首页> 外文OA文献 >221: Preliminary Results of Non-Ablative Conditioning (NAC) with Busulfan (Bu), Fludarabine (Flu) and Alemtuzumab followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease (SCD)

【2h】

221: Preliminary Results of Non-Ablative Conditioning (NAC) with Busulfan (Bu), Fludarabine (Flu) and Alemtuzumab followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease (SCD)

机译：221：白消安（Bu），氟达拉滨（Flu）和Alemtuzumab的非烧蚀性调理（NAC）的初步结果，然后进行异体干细胞移植（AlloSCT），以诱导镰状细胞病（SCD）患者混合供体嵌合。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Bhatia M.; Baldinger L.; Billote G.; Morris E.; Bradley M.B.; George D.; Garvin J.; Satwani P.; Schwartz J.; Wolownik K.; Foley S.; Hawks R.; Baxter-Lowe L.A.; Cairo M.S.;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback in Children and Adolescents with High Risk Sickle Cell Disease (SCD): Rapid Engraftment, Immune Cell Reconstitution, and Sustained Donor Chimerism (IND 14359) [J] . Ayello Janet, Chu Yaya, Keever-Taylor Carolyn A., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：利用高风险镰状细胞病（SCD）的儿童和青少年，利用CD34富集和PB MNC加法进行家族单倍体（FHI）同种异体干细胞移植（AlloSCT）：快速植入，免疫细胞重建和持续的供体嵌合体（IND 14359）
2. More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT) [J] . Jeremy Pappacena, Valkal Bhatt, Gunjan L. Shah, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：更加强烈的氟纳比林/母艇（Flu / Bu）调理方案导致类似的结果，而不是在接受同种异体造血细胞移植（Allo-Hct）的血糖胺/ Melphalan（Flu / Mel）时添加严重毒性
3. More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT) [J] . Jeremy Pappacena, Valkal Bhatt, Gunjan L. Shah, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：更加强烈的氟纳比林/母艇（Flu / Bu）调理方案导致类似的结果，而不是在接受同种异体造血细胞移植（Allo-Hct）的血糖胺/ Melphalan（Flu / Mel）时添加严重毒性
4. Fludarabine Phosphete and Melphalan - An Immunosuppressive Reduced Intensity Conditioning (RIC) Regimen for AUogeneic Stem Cell Transplantation in Patients with a Range of Hematological Malignancies [C] . G. Jackson, C. Richardson, G. Morgan, European Haematology Association . 2002

机译：Fludarabine phospete和Melphalan - 一种免疫抑制性降低的强度调理（RIC）治疗患者血液学恶性肿瘤患者的促孕酮干细胞移植方案
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Experience with Alemtuzumab Fludarabine and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease Stem Cell Source and Alemtuzumab Regimen [O] . Rebecca A. Marsh, Marepalli B. Rao, Aharon Gefen, -1

机译：在非恶性疾病患者中使用Alemtuzumab氟达拉滨和美法仑降低强度的条件进行造血细胞移植的经验显示出良好的结果并且混合嵌合体的风险取决于基础疾病干细胞来源和Alemtuzumab方案
7. A Pilot Study of Reduced Intensity Conditioning (RI) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism in Patients With Symptomatic Sickle Cell Disease (SCD) [O] . Bhatia M., Morris E., Moore V., 2009

机译：先兆研究用白消安（Bu），氟达拉滨（Flu）和Alemtuzumab降低强度调节（RI），然后进行同种异体干细胞移植（AlloSCT）以诱导有症状镰状细胞病（SCD）的患者持续混合供体嵌合。

221: Preliminary Results of Non-Ablative Conditioning (NAC) with Busulfan (Bu), Fludarabine (Flu) and Alemtuzumab followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease (SCD)

著录项

引文网络

相似文献

相关主题

期刊订阅